Mallinckrodt PLC

Over the last three presidential administrations, the United States government has granted Mallinckrodt Pharmaceutical Company 11 special licenses to do business in Iran. (New York Times, "Companies with Permission to Bypass Sanctions," 12/24/10) (http://www.nytimes.com/interactive/2010/12/24/world/24-sanctions-list.html)

According to its Annual Report filed with the SEC for fiscal year 2014: "In late February 2014, Mallinckrodt discovered that one of its non-U.S. subsidiaries, Mallinckrodt Medical B.V. ("MBV"), made sales of medical devices used for brachytherapy to a Dutch customer that subsequently delivered the devices to hospitals in Iran. These hospitals may be owned or controlled, directly or indirectly, by the Iranian government. MBV made 12 such sales during the fiscal year ended September 27, 2013 (resulting in net sales of approximately $25.7 thousand), and we estimate the net profit from these sales was less than that amount. Additionally, two such sales occurred during the three months ended March 28, 2014 (resulting in net sales of approximately $4.5 thousand) and we estimate the net profit from the sales were less than that amount. MBV has not made additional sales to Iran since the activity was discovered in late February 2014, and the company intends to apply for a specific license from the Office of Foreign Assets Control ("OFAC") to continue these activities in the future. Mallinckrodt plc has filed a voluntary self-disclosure with OFAC regarding these activities, and intends to cooperate fully with OFAC." (https://www.sec.gov/Archives/edgar/data/1567892/000156789214000016/mnkq210-q032814.htm)